Krsnaa Diagnostics reported a 22% revenue jump in Q1 FY27 to Rs 2,355.32 million. However, net profit declined 19% to Rs 165.51 million. The company also approved issuing warrants to promoters and declared a final dividend.
Krsnaa Diagnostics Q1 FY27 Results: Revenue Jumps 22%, Profit Declines 19%
Revenue from operations for Krsnaa Diagnostics Ltd rose 22.05% to Rs 2,355.32 million for the first quarter of FY27. Net profit, however, saw a 19.34% decrease to Rs 165.51 million compared to Rs 205.20 million in the same period last year. Reader Takeaway: Strong revenue growth offset by profit dip; watch tax appeals and warrant issuance. ## What just happened Krsnaa Diagnostics announced its financial results for the quarter ended June 30, 2026. Consolidated revenue increased by 22.05% year-on-year to Rs 2,355.32 million. Conversely, consolidated net profit (PAT) declined by 19.34% to Rs 165.51 million. The basic earnings per share (EPS) for the quarter was Rs 5.10, down from Rs 6.35 in Q1 FY26. ## Why this matters The divergence between revenue growth and profit decline indicates potential margin pressures or increased costs. The approval of warrants to promoters is a significant move that could lead to equity dilution or a capital infusion, depending on the conversion. The tax demand notice, although contested, represents a contingent liability. ## The backstory In the previous fiscal year, Krsnaa Diagnostics focused on expanding its diagnostic network. The company has been navigating regulatory environments, including tax assessments, which are common in the healthcare sector. ## What changes now The issuance of 1,621,000 warrants to promoters, Mr. Rajendra Mutha and Krsnaa Diagnostics (Mumbai) Private Limited, at a floor price of Rs 565 per share or SEBI regulatory price, will be a key event. These warrants are convertible into equity shares within 18 months. The company also declared a final dividend of Rs 2.00 per share, with a record date of September 18, 2026. The 16th Annual General Meeting (AGM) is scheduled for September 28, 2026. ## Risks to watch A significant risk highlighted is the tax demand of Rs 626.90 million from tax assessment orders for various years. While the management is contesting these, a negative outcome could impact the company's financial position. The conversion price of warrants and the timing of conversion also remain factors to watch. ## Peer comparison While specific peer results for Q1 FY27 are not provided in the filing, the diagnostic sector typically sees competition from players like Dr. Lal PathLabs and Metropolis Healthcare. Revenue growth is a common objective, but margin management is crucial given operational costs. ## Context metrics (time-bound) Revenue from operations stood at Rs 2,355.32 million in Q1 FY27, up from Rs 1,929.78 million in Q1 FY26. Net Profit (PAT) was Rs 165.51 million in Q1 FY27, down from Rs 205.20 million in Q1 FY26. Earnings Per Share (EPS) basic was Rs 5.10 in Q1 FY27, compared to Rs 6.35 in Q1 FY26. The company plans to issue up to 1,621,000 warrants to promoters. A final dividend of Rs 2.00 per share has been declared. The AGM is scheduled for September 28, 2026. ## What to track next Investors will be closely watching the outcome of the tax appeals and the conversion of the promoter warrants. The company's ability to improve profitability while maintaining revenue growth will be critical.
